SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sund Johan)
 

Sökning: WFRF:(Sund Johan) > The prognostic impa...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00017814naa a2200925 4500
001oai:DiVA.org:uu-442108
003SwePub
008210510s2021 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:ef273d09-5417-442b-98c1-c7a75955763b
009oai:prod.swepub.kib.ki.se:146238106
009oai:DiVA.org:umu-181740
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4421082 URI
0247 a https://doi.org/10.1016/j.ebiom.2021.1032692 DOI
0247 a https://lup.lub.lu.se/record/ef273d09-5417-442b-98c1-c7a75955763b2 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1462381062 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1817402 URI
040 a (SwePub)uud (SwePub)lud (SwePub)kid (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Micke, Patricku Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)patmi676
2451 0a The prognostic impact of the tumour stroma fraction :b A machine learning-based analysis in 16 human solid tumour types
264 1b Elsevier,c 2021
338 a electronic2 rdacarrier
520 a Background: The development of a reactive tumour stroma is a hallmark of tumour progression and pronounced tumour stroma is generally considered to be associated with clinical aggressiveness. The variability between tumour types regarding stroma fraction, and its prognosis associations, have not been systematically analysed.Methods: Using an objective machine-learning method we quantified the tumour stroma in 16 solid cancer types from 2732 patients, representing retrospective tissue collections of surgically resected primary tumours. Image analysis performed tissue segmentation into stromal and epithelial compartment based on pan-cytokeratin staining and autofluorescence patterns.Findings: The stroma fraction was highly variable within and across the tumour types, with kidney cancer showing the lowest and pancreato-biliary type periampullary cancer showing the highest stroma proportion (median 19% and 73% respectively). Adjusted Cox regression models revealed both positive (pancreato-biliary type periampullary cancer and oestrogen negative breast cancer, HR(95%CI)=0.56(0.34-0.92) and HR (95%CI)=0.41(0.17-0.98) respectively) and negative (intestinal type periampullary cancer, HR(95%CI)=3.59 (1.49-8.62)) associations of the tumour stroma fraction with survival.Interpretation: Our study provides an objective quantification of the tumour stroma fraction across major types of solid cancer. Findings strongly argue against the commonly promoted view of a general associations between high stroma abundance and poor prognosis. The results also suggest that full exploitation of the prognostic potential of tumour stroma requires analyses that go beyond determination of stroma abundance.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng
653 a Pathology
653 a Patologi
7001 a Strell, Carinau Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)carst810
7001 a Mattsson, Johanna Sofia Margareta,d 1985-u Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)johma961
7001 a Martin-Bernabe, Alfonsou Karolinska Institutet,Karolinska Institute,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.,Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Brunnström, Hansu Lund University,Lunds universitet,Förbättrad diagnostik och prognostik vid lungcancer och metastaser till lunga,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Improved diagnostics and prognostics of lung cancer and metastases to the lungs,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Department of Clinical Sciences Lund, Division of Pathology, Lund University, Lund, Sweden; Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, Lund, Sweden,Lund Univ, Dept Clin Sci Lund, Div Pathol, Lund, Sweden.;Dept Genet & Pathol, Div Lab Med, Lund, Sweden.4 aut0 (Swepub:lu)med-hsb
7001 a Huvila, Juttau Univ British Columbia, Dept Pathol, Vancouver, BC, Canada.;Univ Turku, Dept Pathol, Turku, Finland.,Department of Pathology, University of British Columbia, Vancouver, Canada; Department of Pathology, University of Turku, Turku, Finland,University of British Columbia4 aut
7001 a Sund, Malinu Umeå universitet,Umeå University,Umeå Univ, Dept Surg & Perioperat Sci Surg, Umeå, Sweden.,Enheten för biobanksforskning,Kirurgi4 aut0 (Swepub:umu)masu0021
7001 a Wärnberg, Fredriku Sahlgrenska Univ Hosp Göteborg, Inst Clin Sci, Dept Surg, Gothenburg, Sweden.,Department of Surgery at Institute of Clinical Sciences, Sahlgrenska University Hospital Göteborg, Göteborg, Sweden4 aut
7001 a Ponten, Fredriku Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Fredrik Pontén,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)fredpont
7001 a Glimelius, Bengtu Uppsala University,Uppsala universitet,Experimentell och klinisk onkologi,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)bengglim
7001 a Hrynchyk, Inau City Clin Pathologoanat Bur, Minsk, BELARUS.,City Clinical Pathologoanatomic Bureau, Minsk, Belarus4 aut
7001 a Mauchanski, Siarheiu NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS.,N.N. Alexandrov Research Institute of Oncology and Medical Radiology,N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus4 aut
7001 a Khelashvili, Salomeu NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS.,N.N. Alexandrov Research Institute of Oncology and Medical Radiology,N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus4 aut
7001 a Garcia-Vicien, Gemmau Catalan Inst Oncol, Program Canc Therapeut Resistance, IDIBELL,ProCURE, Mol Mech & Expt Therapy Oncol Program ONCOBELL, Barcelona, Spain.,ProCURE, Program Against Cancer therapeutic Resistance, Catalan Institute of Oncology, Molecular Mechanisms and Experimental Therapy in Oncology Program (ONCOBELL), IDIBELL, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain,Bellvitge Biomedical Research Institute4 aut
7001 a Mollevi, David G.u Catalan Inst Oncol, Program Canc Therapeut Resistance, IDIBELL,ProCURE, Mol Mech & Expt Therapy Oncol Program ONCOBELL, Barcelona, Spain.,Bellvitge Biomedical Research Institute,ProCURE, Program Against Cancer therapeutic Resistance, Catalan Institute of Oncology, Molecular Mechanisms and Experimental Therapy in Oncology Program (ONCOBELL), IDIBELL, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain4 aut
7001 a Edqvist, Per-Henrik Du Karolinska Institutet,Uppsala University,Uppsala universitet,Experimentell och klinisk onkologi,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)peedq227
7001 a Reilly, Aine O.u Karolinska Institute,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.,Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Corvigno, Sarau Uppsala University,Uppsala universitet,Institutionen för immunologi, genetik och patologi,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.,Karolinska University Hospital,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Dahlstrand, Hannau Uppsala University,Karolinska Institute,Uppsala universitet,Experimentell och klinisk onkologi,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut0 (Swepub:uu)handa983
7001 a Botling, Johanu Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Johan Botling,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)johanbot
7001 a Segersten, Ulrikau Uppsala University,Uppsala universitet,Urologkirurgi,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)ulriande
7001 a Krzyzanowska, Agnieszkau Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Translat Med, Div Urol Canc, Lund, Sweden.,Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden4 aut0 (Swepub:lu)med-aky
7001 a Bjartell, Andersu Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Translat Med, Div Urol Canc, Lund, Sweden.,Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden4 aut0 (Swepub:lu)kir-abj
7001 a Elebro, Jacobu Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)med-jce
7001 a Heby, Margaretau Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)med-mh11
7001 a Lundgren, Sebastianu Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)se2285lu
7001 a Hedner, Charlottau Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)med-cah
7001 a Borg, Davidu Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)onk-dbo
7001 a Brändstedt, Jennyu Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)med-jyb
7001 a Sartor, Hannau Lund University,Lunds universitet,Diagnostisk radiologi, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Radiology Diagnostics, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Diagnostic Radiology, Department of Translational Medicine, Lund University, Skåne University Hospital, Lund, Sweden,Lund Univ, Skane Univ Hosp, Dept Translat Med, Diagnost Radiol, Lund, Sweden.4 aut0 (Swepub:lu)med-hso
7001 a Malmström, Per-Unou Uppsala University,Uppsala universitet,Urologkirurgi,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)perunoms
7001 a Johansson, Martinu Sahlgrenska Univ Hosp Göteborg, Inst Biomed, Dept Lab Med, Gothenburg, Sweden.,Department of Laboratory Medicine at Institute of Biomedicine, Sahlgrenska Universitety Hospital Göteborg, Göteborg, Sweden4 aut
7001 a Nodin, Björnu Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.,Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden4 aut0 (Swepub:lu)immu-bnn
7001 a Backman, Maxu Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)maxba655
7001 a Lindskog, Ceciliau Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)cecli129
7001 a Jirström, Karinu Lund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Department of Genetics and Pathology, Division of Laboratory Medicine, Region Skåne, Lund, Sweden; Department of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden,Dept Genet & Pathol, Div Lab Med, Lund, Sweden.;Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, SE-22100 Lund, Sweden.4 aut0 (Swepub:lu)pat-kji
7001 a Mezheyeuski, Arturu Uppsala University,Uppsala universitet,Experimentell och klinisk onkologi,Uppsala Univ, Dept Immunol Genet & Pathol, S-75185 Uppsala, Sweden.,Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)artme913
7102 a Uppsala universitetb Klinisk och experimentell patologi4 org
7730 t EBioMedicined : Elsevierg 65q 65x 2352-3964
8564 u https://doi.org/10.1016/j.ebiom.2021.103269y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1553655/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://www.thelancet.com/article/S2352396421000621/pdf
8564 u http://dx.doi.org/10.1016/j.ebiom.2021.103269x freey FULLTEXT
8564 u https://umu.diva-portal.org/smash/get/diva2:1539246/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-442108
8564 8u https://doi.org/10.1016/j.ebiom.2021.103269
8564 8u https://lup.lub.lu.se/record/ef273d09-5417-442b-98c1-c7a75955763b
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:146238106
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-181740

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy